Cancer Prevention and Control Program/University of South Carolina
Columbia, South Carolina, 29208, United States
NCT Number: NCT01195077
Drawing inferences from epidemiologic studies of HIV/AIDS as well well as cell culture and animal studies of HIV inhibition by algae, we propose algal consumption as one unifying characteristic of countries with anomalously low rates. HIV/AIDS incidence and prevalence in Eastern Asia (<1/10,000 adults in Japan and Korea), compared to Africa (≈1/10 adults) strongly suggest that differences in IV drug use and sexual behavior are insufficient to explain the 1000-fold variation. Even in Africa, AIDS/HIV rates vary. Spirulina is part of the daily diet for many people living in Chad, where prevalence of HIV has remained at less than 4% for more than 20 years. Average daily algae consumption in Asia and Africa ranges between 1 to 2 tablespoons (3 - 13 grams).
HIV viral load is the main indicator of infection, however CD4 helper cell counts are most predictive of morbidity and mortality.We hypothesized that the consumption of algae could be important in diminishing the risk of HIV infection, and subsequent progression, possibly by enhancing the immune response.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 1 / Phase 2
Columbia, South Carolina, 29208, United States
Twelve HIV+ patients not on antiretroviral therapy were clinically evaluated and enrolled in the three-week study. Subjects received 10 algae capsules/d. Laboratory tests of CD4 counts and HIV RNA were performed at baseline, week 1, week 2, and week 3, and then once a month. Six subjects continued for between 4 and 14 months. In addition to CD4 lymphocyte counts and viral loads, subjects were evaluated monthly for Complete Blood Counts (CBC), Liver profile, Basic Metabolic Panel, and some subjects were evaluated for thyroid function and cholesterol. All subjects completed standard HIV Quality of Life questionnaires at each clinic visit.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Arm 1: Seaweed. Ten capsules of .5 grams per capsule for a total of 10 grams per day.
Arm 2: Spirulina: Ten capsules of .5 grams per capsule for a total of 10 grams per day.
Arm 3: Seaweed: (2.5 grams) plus Spirulina (2.5 grams). Ten capsules of .5 grams per capsule for a total of 10 grams per day.
Spirulina: Ten capsules of .5 grams per capsule for a total of 10 grams per day.
Time frame: Once a week for first 3 weeks, then once a month
The first 6 subjects participated for 3 weeks. After analysis of the results, it was determined that there were no side effects and some indication of benefit. The next 6 subjects participated for up to 14 months.
Time frame: Participants were randomized to one of 3 treatments.
The combination of the 2 algae appeared to have more benefit. However, the sample size was too small to make conclusions.
University of South Carolina
Other
Acronym: HIV
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03048422
Blood-Borne Infections, Communicable Diseases
Jacksonville, Florida, United States
View Trial DetailsNCT05388474
Blood-Borne Infections, Communicable Diseases
Los Angeles, California, United States
View Trial DetailsNCT03284710
Blood-Borne Infections, Communicable Diseases
Maputo, Mozambique
View Trial DetailsNCT02591420
Blood-Borne Infections, Communicable Diseases
Kericho, Kenya
View Trial Details